Advances in the Use of Targeted Therapies in the Management of Non-Small Cell Lung Cancer

摘要

Advances in tumor genetics and molecular biology created the potential to identify mutations associated with carcinogenesis and tumor progression and to develop therapies that target the mutations. Improved understanding of tumor genetics has had a major impact on the treatment of non-small cell lung cancer (NSCLC), as clinicians can offer patients a variety of active mutation-targeted therapies, even for patients, with advanced disease. At JADPRO Live 2017, Heather Wake-lee, MD, of Stanford University, Stanford Cancer Institute in Stanford, California, and Elizabeth S. Waxman, RN, MSN, AOCN, ANP-BC, of The University of Texas MD Anderson Cancer Center in Houston, discussed the latest developments in the use of targeted therapies to treat NSCLC.